Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pasithea Therapeutics Equity Warrant Exp 11th Aug 2026 KTTAW

Healthcare Biotechnology
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small... see more

Recent & Breaking News (NDAQ:KTTAW)

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

GlobeNewswire May 3, 2023

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

GlobeNewswire March 2, 2023

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

GlobeNewswire February 23, 2023

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

GlobeNewswire February 16, 2023

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

GlobeNewswire January 18, 2023

Majority of Stockholders Support Pasithea Directors at Special Meeting

GlobeNewswire December 14, 2022

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

GlobeNewswire December 12, 2022

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

GlobeNewswire December 6, 2022

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

GlobeNewswire November 28, 2022

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

GlobeNewswire October 17, 2022

Pasithea Therapeutics Acquires AlloMek Therapeutics

GlobeNewswire October 12, 2022

Pasithea Therapeutics to Call Special Meeting of Stockholders

GlobeNewswire October 3, 2022

Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

GlobeNewswire September 20, 2022

Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz

GlobeNewswire September 15, 2022

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 9, 2022

Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference

GlobeNewswire August 18, 2022

Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

GlobeNewswire August 11, 2022

Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group's Unjustified Campaign

GlobeNewswire August 2, 2022

Pasithea Therapeutics Awarded a Drug Development Research Grant

GlobeNewswire July 14, 2022

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

GlobeNewswire June 23, 2022